Merck & Co. vs Novo Nordisk A/S: Business Model & Financial Comparison 2026
Merck & Co. · Healthcare / Drug Manufacturers - General·Novo Nordisk A/S · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | MRKMerck & Co. | NVONovo Nordisk A/S |
|---|---|---|
| Market Cap | $285.83B | $169.29B |
| Revenue (TTM) | $65.01B | $309.06B |
| Revenue Growth | 5.0% | -7.6% |
| Gross Margin | 77.2% | 82.4% |
| Operating Margin | 32.8% | 44.5% |
| Net Margin | 28.1% | 33.1% |
| Return on Equity | 36.9% | 60.7% |
| P/E (Trailing) | 15.9x | 10.7x |
| P/E (Forward) | 11.8x | 11.4x |
| Free Cash Flow | $11.89B | $376.9M |
| Cash | $14.57B | $26.96B |
| Total Debt | $50.53B | $130.96B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Merck & Co.
Merck & Co., Inc. stands as a leading company in Healthcare. Generating $65.01 billion in annual revenue (growing 5.0% year-over-year) and carrying a market capitalization of $286.97 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Merck & Co., Inc. continues to execute on a multi-year strategic vision that balances growth inv…
Full Merck & Co. analysis →Novo Nordisk A/S
Novo Nordisk A/S stands as a leading company in Healthcare. Generating $309.06 billion in annual revenue (growing -7.6% year-over-year) and carrying a market capitalization of $173.66 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Novo Nordisk A/S continues to execute on a multi-year strategic vision that balances growth inv…
Full Novo Nordisk A/S analysis →SWOT Analysis Comparison
Strengths
Merck & Co.
- With a market capitalization of $286.97B, Merck & Co., Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access th
- Merck & Co., Inc.'s gross margin of 77.2% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 32.8% demonstrates dis
- A return on equity of 36.9% demonstrates that Merck & Co., Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Novo Nordisk A/S
- With a market capitalization of $173.66B, Novo Nordisk A/S is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access tha
- Novo Nordisk A/S's gross margin of 82.4% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.5% demonstrates disc
- A return on equity of 60.7% demonstrates that Novo Nordisk A/S generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Weaknesses
Merck & Co.
- Merck & Co., Inc.'s debt-to-equity ratio of 96.0 indicates meaningful financial leverage. Total debt stands at $50.53B against $14.57B in cash and equivalents.
Novo Nordisk A/S
- Novo Nordisk A/S's debt-to-equity ratio of 67.5 indicates meaningful financial leverage. Total debt stands at $130.96B against $26.96B in cash and equivalents.
- Year-over-year revenue declined 7.6%, raising questions about demand for Novo Nordisk A/S's core offerings and requiring management to articulate a credible recovery path.
Opportunities
Merck & Co.
- Merck & Co., Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in th
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Merck &
- With $14.57B in cash and strong free cash flow generation, Merck & Co., Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Novo Nordisk A/S
- Novo Nordisk A/S operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in thi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Novo No
- With $26.96B in cash and strong free cash flow generation, Novo Nordisk A/S is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Threats
Merck & Co.
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Merck & Co., Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recessio
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Merck & Co., Inc.'s
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Novo Nordisk A/S
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Novo Nordisk A/S's revenue is not fully insulated from macroeconomic cycles, and a recession
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Novo Nordisk A/S's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolMerck & Co. vs Novo Nordisk A/S: FAQ
- Is Merck & Co. bigger than Novo Nordisk A/S?
- By market capitalization, Merck & Co. is larger at $285.83B vs Novo Nordisk A/S's $169.29B.
- Which has better profit margins — Merck & Co. or Novo Nordisk A/S?
- Novo Nordisk A/S has higher net profit margins (33.1%) compared to Merck & Co. (28.1%). Gross and operating margins are compared in the table above.
- What sectors do Merck & Co. and Novo Nordisk A/S operate in?
- Merck & Co. operates in the Healthcare sector (Drug Manufacturers - General). Novo Nordisk A/S operates in the Healthcare sector (Drug Manufacturers - General).
- How does Merck & Co.'s revenue compare to Novo Nordisk A/S's?
- Merck & Co. generates $65.01B in annual revenue (TTM) while Novo Nordisk A/S generates $309.06B. Novo Nordisk A/S is the larger company by revenue as of 2026.